Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Glömd dos hos patienter med plackpsoriasis

Taltz Produktresumé innehåller ingen särskild rekommendation om vad man ska göra när en patient glömmer en dos av ixekizumab.

Additional Information

  • The US Taltz package insert states that if a dose is missed, the dose should be administered as soon as possible. Thereafter, resume dosing at the regular scheduled time.1

  • In the ixekizumab clinical development program, ixekizumab was administered at approximately the same time each day, as much as possible.2,3

  • For the pivotal UNCOVER adult psoriasis clinical trials, injections not administered on the scheduled day were to be administered

    • within 1 to 3 days of the scheduled day during the induction period (week 0-12), and

    • within 5 days of the scheduled day after week 12.2

Therapeutic Indication

Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.4


1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

2. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M02 12

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss